Longitudinal — Multi-Year Readout
The first ninety days answer the early-window question. The long-arc question is read differently: DEXA timing, biomarker pacing, sleep-architecture drift, and the symptom-trajectory reads at month 3 / 6 / 12. This is the framing for that multi-year thread — across perimenopause, menopause, and postmenopause, on the same record.
What the science actually says
Peptide approaches are read against biomarker pacing rather than a single point-in-time test. The first six to eight weeks are the early-window calibration; month three is the first real read; month six is where cumulative effects start to show across the approach's monthly surface; twelve months is when the multi-axis story starts to crystallize. The cadence itself shapes what a curator can read against.
At month three a baseline read against cycle phase, sleep intervals, and recovery curve is taken. By month six inflammatory markers, lipids, and HbA1c come into the picture. At twelve months DEXA, telomere-attrition pace, and the bone density readout crystallize. None of these are read in isolation — they are read together against the same record, with the approach continuity thread visible throughout.
The published peptide literature is uneven across the multi-year dimensions that midlife women care about. Khavinson group's Epitalon work includes longitudinal data, MOTS-c is increasingly studied over months, and the BPC-157 / Recovery literature has the deepest wound-healing and tendon-recovery timelines. Reading the evidence means knowing which approach has longitudinal data and which is read from mechanism and adjacent-indication inference.
A woman whose approach needs continuity across the perimenopause-to-postmenopause arc needs a single record, one curator, and the multi-axis monthly review at 3 / 6 / 12. This is the approach-continuity profile: she is a candidate for the approach that holds its shape across the calendar. Not a 30-day tester; not a six-month trial-tester; a woman playing the long game with the formula adjustable to her own multi-year data.
Where this sits alongside
the approach continuity thesis — the same curator, same intake, theme-over-time — is on Continuity Across Stages →; the early-window framing that pairs against the long-arc one is First 90 Days →; and the peer-reviewed citation layer behind these reads is Research Library →.
Continuity across stages names what the multi-year thread implies: one subscription, one record, theme-over-time. The thread isn't a feature we add in marketing; it is the geometry of care that women's biology actually requires. The longitudinal framing is the read against that geometry.
Read Continuity Across Stages →The first ninety days are the early-window calibration that the multi-year thread is built on. Reading the first three months against the long arc keeps both ends of the conversation calibrated — what the recovery looks like at week six and where the trajectory is heading at month twelve are reads of the same approach, not two separate ones.
Read First 90 Days →The Research Library page is the citation layer that makes the longitudinal framing credible. Every biomarker-pacing reference and every multi-axis read has a peer-reviewed source that the intake review references. Reading the approaches against the evidence means knowing which claims have multi-year data and which are read from mechanism and adjacent indication.
Read Research Library →What to read next
The published peptide research, organized by approach — use it alongside the longitudinal frame to read claims at their actual evidence depth.
Read Research Library →The early window is when most women decide whether a approach is for them; this is the companion read for the long-arc one.
Read First 90 Days →The most quantified readout of a postmenopausal approach is bone density; this is the deep-dive on that specific trajectory.
Read Bone Density →Read it on a multi-year thread
The structured intake reads your hormonal baseline, your last biomarker panel, your recovery and sleep signals, and your goals across the multi-year thread. One curator, one record, one plan that reads what the science supports rather than reaching for a peptide first.
Most women hear back within one business day. Confidential. Reviewed personally.